Chaga Mushroom Powder fruitbody powder standardized to Pure Beta Glucan >8% is an Inonotus obliquus ingredient for food supplements and functional foods that need a clear fruitbody beta-glucan marker instead of a generic mushroom blend. Its best commercial fit is antioxidant, immune, and general-resilience mushroom wellness in capsules, tablets, sachets, coffee/cocoa systems, and tea-latte powder blends. Quality limits are controlled for moisture <9.0%, total ash <9.0%, heavy metals, pesticide residue <LOQ, and the stated microbiological limits in the COA.

*Study doses in the literature may use species-specific powders or extracts rather than this exact batch. For this shop SKU, a practical general range is 500-3000 mg/day unless the finished formula supports a different serving size.

How it works

1. Standardized beta-glucan marker: The beta-glucan specification above 8% gives formulators a measurable polysaccharide marker for batch control and claim discipline.
2. Species-specific fruitbody matrix: Chaga is often associated with a dark phenolic profile, which helps explain both antioxidant use and strong color impact in finished formulas.
3. Finished-product serving reality: For mushroom powders, the main technical decision is usually realistic serving design and sensory fit, not exotic chemical stabilization.

How to use and key cautions

• Usual supplemental range: A practical general range is 500-3000 mg/day (0.5-3.0 g/day).
• Best product formats: Best fit is capsules, tablets, sachets, coffee/cocoa systems, and tea-latte powder blends; choose formats that can deliver the target serving without making the product too bulky or hard to mix.
• Formulation advice: Best fit is in capsules, dark drink powders, cocoa blends, and sachets; avoid pale-clear systems where the color and insoluble solids become a visual penalty.
• Processing and taste: Manage sediment expectations, preblend for uniform dispersion, and consider flavor-masking because Chaga can bring woody-earthy notes.
• Who should use extra caution: Use caution for people with kidney-stone risk, anticoagulants, or glucose-lowering therapy, and keep claims well away from disease-treatment language.